



## **Solenio Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference**

March 25, 2019 12:00 PM EDT

REDWOOD CITY, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the ROTH Battle of NASH Thrones Spring Investor Conference, taking place on Thursday, March 28, 2019, in New York. The event will include panel discussions and Soleno will host 1x1 meetings with investors at the conference.

### **About Soleno Therapeutics, Inc.**

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit [www.solenio.life](http://www.solenio.life).

### **CONTACT:**

Brian Ritchie  
LifeSci Advisors, LLC  
212-915-2578



Source: Soleno Therapeutics